- Home
- VRNS vs ALKS Comparison
VRNS vs ALKS Comparison
Compare VRNS & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNS
- ALKS
- Stock Information
- Founded
- VRNS 2004
- ALKS 1987
- Country
- VRNS United States
- ALKS Ireland
- Employees
- VRNS N/A
- ALKS N/A
- Industry
- VRNS Computer Software: Prepackaged Software
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- VRNS Technology
- ALKS Health Care
- Exchange
- VRNS Nasdaq
- ALKS Nasdaq
- Market Cap
- VRNS 4.4B
- ALKS 5.1B
- IPO Year
- VRNS 2014
- ALKS 1991
- Fundamental
- Price
- VRNS $49.58
- ALKS $30.28
- Analyst Decision
- VRNS Buy
- ALKS Buy
- Analyst Count
- VRNS 18
- ALKS 12
- Target Price
- VRNS $55.35
- ALKS $40.00
- AVG Volume (30 Days)
- VRNS 1.4M
- ALKS 1.9M
- Earning Date
- VRNS 07-29-2025
- ALKS 07-23-2025
- Dividend Yield
- VRNS N/A
- ALKS N/A
- EPS Growth
- VRNS N/A
- ALKS N/A
- EPS
- VRNS N/A
- ALKS 2.09
- Revenue
- VRNS $573,351,000.00
- ALKS $1,513,770,000.00
- Revenue This Year
- VRNS $14.93
- ALKS N/A
- Revenue Next Year
- VRNS $16.47
- ALKS $4.25
- P/E Ratio
- VRNS N/A
- ALKS $14.45
- Revenue Growth
- VRNS 13.35
- ALKS N/A
- 52 Week Low
- VRNS $36.53
- ALKS $22.97
- 52 Week High
- VRNS $60.58
- ALKS $36.45
- Technical
- Relative Strength Index (RSI)
- VRNS 48.46
- ALKS 55.80
- Support Level
- VRNS $49.90
- ALKS $28.67
- Resistance Level
- VRNS $53.90
- ALKS $30.90
- Average True Range (ATR)
- VRNS 1.34
- ALKS 0.68
- MACD
- VRNS -0.12
- ALKS 0.18
- Stochastic Oscillator
- VRNS 19.91
- ALKS 71.78
About VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.